Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER study.
Canino F, Barbolini M, De Giorgi U, Fontana T, Gaspari V, Gianni C, Gianni L, Maestri A, Minichillo S, Moscetti L, Mura A, Nicoletti SVL, Omarini C, Pagani R, Sarti S, Toss A, Zamagni C, Cuoghi Costantini R, Caggia F, Antonelli G, Baglio F, Belluzzi L, Martinelli G, Natalizio S, Ponzoni O, Dominici M, Piacentini F.
Canino F, et al. Among authors: gianni l.
BMC Cancer. 2024 Jun 15;24(1):735. doi: 10.1186/s12885-024-12506-0.
BMC Cancer. 2024.
PMID: 38879498
Free PMC article.